



Long-Term Drug Shortage – Cystaran® (cysteamine)

- The [drug shortage](#) of Leadiant's [Cystaran \(cysteamine\)](#) 0.44% ophthalmic solution is ongoing. Cystaran has been unavailable due to an independent manufacturer declaring bankruptcy.
 - Leadiant is working with a different manufacturer to restart production and they do not have an estimated date of availability.
- An alternative, [Cystadrops \(cysteamine\)](#) 0.37% ophthalmic solution made by Recordati is available.
- Per Leadiant and Recordati, patients using Cystaran have been switched to the alternative Cystadrops.
- Cysteamine ophthalmic solution is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis, a rare genetic disorder. Cystaran and Cystadrops are only available through limited distribution channels.

Product Description	NDC#
Cystaran (cysteamine) 0.44% ophthalmic solution	54482-0020-01
Cystadrops (cysteamine) 0.37% ophthalmic solution	55292-0410-05



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.